LOXO Oncology Growth, Revenue, Number of Employees and Funding

Overview

Location:
Total Funding:$125.3M
Industry:Pharma
Founded:2013
Lead Investor(s):Morgan Stanley
Press

Industry Ranking

State Ranking

Growjo 10k Ranking

Revenue & Financials

  • LOXO Oncology's revenue is currently $23.4M per year.
  • LOXO Oncology received $294.8M in venture funding in June 2017.
  • LOXO Oncology's revenue per employee is $160000
  • LOXO Oncology's total funding is $125.3M.

Employee Data

  • LOXO Oncology has 146 Employees.
  • LOXO Oncology grew their employee count by 74% last year.
  • LOXO Oncology currently has 6 job openings.

What Is LOXO Oncology?

Loxo Oncology is a biopharmaceutical company dedicated to developing highly-selective medicines for patients with genomically defined cancers. Our pipeline is focused on treatments aimed at cancers caused by a single inappropriate DNA change, known as oncogenic drivers, which the tumor depends on for growth and survival. Loxo Oncology develops purpose-built medicines designed to selectively and potently inhibit these oncogenic drivers. We believe that this approach, combined with the use of tumor genomic testing to identify appropriate patients, will allow us to develop medicines that provide best-in-class disease control and safety and, ultimately, deliver on the promise of precision medicine. We are based in Stamford, CT with sites in San Francisco, CA and Boulder, CO. For more information about Loxo Oncology, please visit us at www.loxooncology.com.

keywords:Biotechnology,Healthcare,Pharmaceuticals

146

Number of Employees

$23.4M

Revenue (est)

6

Current Jobs

74%

Employee Growth %

$125.3M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Connecticut Pha...
$6M327%
The Scienomics ...
$18.5M10211%
Avara Pharmaceu...
$134.2M67127%
CE3
$11.3M619%
LOXO Oncology
$23.4M14674%$125.3M

LOXO Oncology News

53 minutes ago - Pitcairn Co. Has $257000 Stake in Loxo Oncology Inc (LOXO)

Pitcairn Co. decreased its position in Loxo Oncology Inc (NASDAQ:LOXO) by 6.8% during the 4th quarter, according to its most recent

20-Mar-19 - Loxo Oncology Inc (LOXO) Receives Consensus Recommendation of

Loxo Oncology Inc (NASDAQ:LOXO) has been assigned a consensus recommendation of “Buy” from the eighteen brokerages that are covering

25-Feb-19 - Bristol-Myers Squibb to acquire Celgene, Eli Lilly to acquire Loxo

Bristol-Myers Squibb to acquire Celgene, Eli Lilly to acquire Loxo Oncology ... history, and Eli Lilly and Co., which has agreed to acquire Loxo Oncology Inc.

LOXO Oncology Funding

DateAmountRoundLead InvestorsReference
2014-05-07$24.0MBNew Enterprise AssociatesArticle
2017-06-22$294.8MUndisclosedMorgan StanleyArticle

LOXO Oncology Executive Hires

DateNameTitleReference
2014-05-07Mikel MoyerChief Scientific OfficerArticle
2014-10-29Jennifer LowChief Medical Officer/EVP R/DArticle